3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Other hematologic neoplasm
1
Lymphoid
1
Dermatologic
1
CNS
1
Conditions
Melanoma
4
Carcinoma, Renal Cell
3
Triple Negative Breast Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Recurrence
2
Neoplasm Metastasis
2
Colorectal Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Unspecified Adult Solid Tumor, Protocol Specific
1
Stomach Neoplasms
1
Sarcoma, Ewing
1
Sarcoma
1
Rhabdomyosarcoma
1
Neuroblastoma
1
Neoplasms
1
Medulloblastoma
1
Lymphoma, Non-Hodgkin
1
Lymphoma
1
Leukemia, B-Cell
1
Leukemia
1
Glioma
1
Ependymoma
1
Carcinoma, Transitional Cell
1
Carcinoma, Merkel Cell
1
Interventions
Temozolomide
8
Irinotecan
7
Vincristine
6
Nivolumab
2
temsirolimus
1
talazoparib
1
surufatinib
1
sonidegib
1
silmitasertib
1
regorafenib
1
prexasertib
1
pegylated granulocyte colony-stimulating factor
1
pegfilgrastim
1
liposomal doxorubicin
1
lenvatinib
1
lentiviral minigene vaccine of COVID-19 coronavirus
1
irinotecan sucrosofate
1
holmium-1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetrakis(methylenephosphonic acid)
1
ganitumab
1
eribulin
1
efineptakin alfa
1
dostarlimab
1
dinutuximab
1
copanlisib
1
bempegaldesleukin
1
atezolizumab
1
adavosertib
1
abemaciclib
1
Zoledronic Acid
1
Vinorelbine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Rhabdomyosarcoma
×
bempegaldesleukin
×
Clear all
NCT04730349
2023-03-24
PIVOT IO 020
Bristol-Myers Squibb
Phase 1/2
Terminated
15 enrolled
14 charts